Paclitaxel, gemcitabine, and cisplatin in non-resectable non-small-cell lung cancer
Open Access
- 1 September 1999
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 10 (9) , 1043-1050
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- A three-week schedule of gemcitabine–cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: A phase II randomized trialAnnals of Oncology, 2000
- Multicentric randomized phase II study with gemcitabine (GEM) plus cisplatin (CDDP) in patients with stage IIIB-IV NSCLCLung Cancer, 1998
- Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.Journal of Clinical Oncology, 1998
- Single agent Taxol, 3-hour infusion, in untreated advanced non-small-cell lung cancerAnnals of Oncology, 1995
- Dose-finding study of paclitaxel (Taxol1) plus cisplatin in patients with non-small cell lung cancerLung Cancer, 1995
- The MIC regimen in non-small cell lung cancerLung Cancer, 1993
- Phase II Study of Taxol in Patients With Untreated Advanced Non-Small-Cell Lung CancerJNCI: Journal of the National Cancer Institute, 1993
- Sequences of taxol and cisplatin: a phase I and pharmacologic study.Journal of Clinical Oncology, 1991
- Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancerBritish Journal of Cancer, 1989
- The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agentJournal of Chronic Diseases, 1961